EuKedos Valuation

Is EUK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EUK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EUK (€0.83) is trading below our estimate of fair value (€3.12)

Significantly Below Fair Value: EUK is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EUK?

Key metric: As EUK is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EUK. This is calculated by dividing EUK's market cap by their current earnings.
What is EUK's PE Ratio?
PE Ratio	26.3x
Earnings	€717.00k
Market Cap	€18.88m

EUK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.4x
Enterprise Value/EBITDA	15.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does EUK's PE Ratio compare to its peers?

The above table shows the PE ratio for EUK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	9.8x
HI Health Italia	14.6x	n/a	€24.6m
SRI Servizi Italia	14.8x	16.9%	€69.0m
IMD I.M.D. International Medical Devices	9.9x	18.6%	€25.6m
IVN iVision Tech	0.02x	n/a	€14.0m
EUK EuKedos	26.3x	n/a	€18.9m

Price-To-Earnings vs Peers: EUK is expensive based on its Price-To-Earnings Ratio (26.3x) compared to the peer average (9.8x).

Price to Earnings Ratio vs Industry

How does EUK's PE Ratio compare vs other companies in the European Healthcare Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: EUK is expensive based on its Price-To-Earnings Ratio (26.3x) compared to the European Healthcare industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is EUK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EUK PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	26.3x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EUK's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Fresenius Medical Care

€12.2b

Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally.

1FME

€41.39

1.4%

15.5%

Amplifon

€5.2b

Engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific.

AMP

€23.26

-3.1%

-17.7%

Garofalo Health Care

€517.2m

Operates healthcare clinics in Italy.

GHC

€5.84

2.1%

30.6%